Artificial intelligence (AI) is already revolutionizing drug discovery and development by accelerating the identification of novel targets, optimizing molecules, and improving the efficiency of clinical trials. AI's ability to sift through vast datasets and identify patterns has opened up new avenues for drug discovery, helping pharma companies reduce the time and cost of bringing therapies to market. However, there is still much to prove in terms of AI’s long-term impact on regulatory approval, trial success rates, and overall drug efficacy. This panel will explore the areas where AI has made the most significant impact - from identifying novel drug targets to speeding up regulatory filings and making clinical trials smarter and more efficient. Panelists will address the successes, challenges, and untapped potential that AI offers in drug development, as well as the critical next steps needed to fully realize its promise.